Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?

Cancer Treatment Reviews

Volumn 37, Issue 7, 2011, Pages 533-542

  Agarwal, Vijay ^a,b   Lind, Michael J ^a,b   Cawkwell, Lynn ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Epidermal growth factor receptor; Mesothelioma; Predictive biomarkers; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; B RAF KINASE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; K RAS PROTEIN; LAPATINIB; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ROFECOXIB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ANGIOGENESIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DRUG DOSE COMPARISON; DRUG TARGETING; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LARGE CELL CARCINOMA; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA MESOTHELIOMA; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80052367585     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.11.004     Document Type: Review

References (116)

1. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
2. Weill H., Hughes J.M., Churg A.M. Changing trends in US mesothelioma incidence. Occup Environ Med 2004, 61:438-441.
3. Carbone M., Kratzke R.A., Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 2002, 29:2-17.
4. Lanphear B.P., Buncher C.R. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992, 34:718-721.
5. De Luca A., Baldi A., Esposito V., et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997, 3:913-916.
6. Testa J.R., Carbone M., Hirvonen A., et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 1998, 58:4505-4509.
7. Dogan A.U., Baris Y.I., Dogan M., et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006, 66:5063-5068.
8. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001, 357:444-445.
9. Ceresoli G.L., Locati L.D., Ferreri A.J., et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001, 34:279-287.
10. Stahel R.A., Weder W., Lievens Y., Felip E. Group ObotEGW. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v126-v128.
11. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
12. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the national cancer institute of Canada. J Clin Oncol 2005, 23:6881-6889.
13. Cohen S. Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA 1960;46:302-11.
14. Carpenter G.K.J.L., Morrison M.M., Cohen S. Characterization of the binding of I25l-labeled epidermal growth factor to human fibroblasts. J Biol Chem 1975, 250:4297-4304.
15. Cohen S., Ushiro H., Stoscheck C., Chinkers M. A native 170, 000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982, 257:1523-1531.
16. Downward J., Yarden Y., Mayes E., et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307:521-527.
17. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
18. Citri A., Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7:505-516.
19. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
20. Bogdan S., Klambt C. Epidermal growth factor receptor signaling. Curr Biol 2001, 11:R292-R295.
21. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
22. Franklin W.A., Veve R., Hirsch F.R., Helfrich B.A., Bunn P.A. Epidermal growth factor receptor family in lung cancer and premalignancy. Seminars in Oncology 2002, 29:3-14.
23. Rusch V., Baselga J., Cordon-Cardo C., et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993, 53:2379-2385.
24. Hirsch F.R., Varella-Garcia M., Bunn P.A., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-3807.
25. Nakamura H., Kawasaki N., Taguchi M., Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006, 61:140-145.
26. Cohen M.H., Williams G.A., Sridhara R., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10:1212-1218.
27. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa(R)) tablets. Oncologist 2003, 8:303-306.
28. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
29. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
30. Cohen M.H., Johnson J.R., Chen Y.-F., Sridhara R., Pazdur R. FDA drug approval summary: erlotinib (Tarceva(R)) tablets. Oncologist 2005, 10:461-466.
31. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 2004, 22:3238-3247.
32. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005, 353:123-132.
33. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). The Lancet 2005, 366:1527-1537.
34. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
35. Ho C., Murray N., Laskin J., Melosky B., Anderson H., Bebb G. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005, 49:225-231.
36. Miller V.A., Kris M.G., Shah N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004, 22:1103-1109.
37. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
38. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
39. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181.
40. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
41. Chan S.K., Gullick W.J., Hill M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006, 42:17-23.
42. Yun C.H., Boggon T.J., Li Y., et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
43. Gazdar A.F., Shigematsu H., Herz J., Minna J.D. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med 2004, 10:481-486.
44. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., Janne P.A. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004, 64:7241-7244.
45. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23:2556-2568.
46. Dahabreh I.J., Linardou H., Siannis F., Kosmidis P., Bafaloukos D., Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010, 16:291-303.
47. Mok T.S., Wu Y.-L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
48. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962-972.
49. Qiu L.-X., Mao C., Zhang J., et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. European Journal of Cancer 2010, 46:2781-2787.
50. Robert F., Blumenschein G., Herbst R.S., et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:9089-9096.
51. Butts C.A., Bodkin D., Middleman E.L., et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007, 25:5777-5784.
52. Rosell R., Robinet G., Szczesna A., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 2008, 19:362-369.
53. Ettinger D.S. Emerging profile of cetuximab in non-small cell lung cancer. Lung cancer 2010, 68:332-337.
54. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet 2009, 373:1525-1531.
55. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
56. Lenz H.J., Van Cutsem E., Khambata-Ford S., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006, 24:4914-4921.
57. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
58. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
59. Tabernero J., Van Cutsem E., Diaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007, 25:5225-5232.
60. Folprecht G., Lutz M.P., Schoffski P., et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006, 17:450-456.
61. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CAmutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet Oncology 2010, 11:753-762.
62. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal Cancer. New England Journal of Medicine 2008, 359:1757-1765.
63. Andreyev H.J., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696.
64. Hawkes E., Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. Journal of Clinical Oncology 2010, 28:e529-e531.
65. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Journal of Clinical Oncology 2009, 27:5924-5930.
66. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
67. Yuen S.T., Davies H., Chan T.L., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62:6451-6455.
68. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
69. Loupakis F., Ruzzo A., Cremolini C., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009, 101:715-721.
70. Tol J., Nagtegaal I.D., Punt C.J. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009, 361:98-99.
71. Markman B., Atzori F., Pérez-García J., Tabernero J., Baselga J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Annals of Oncology 2010, 21:683-691.
72. Perrone F., Lampis A., Orsenigo M., et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009, 20:84-90.
73. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
74. Zhang S., Yu D. PI(3)king apart PTEN's role in cancer. Clinical Cancer Research 2010, 16:4325-4330.
75. Frattini M., Saletti P., Romagnani E., et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007, 97:1139-1145.
76. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. Journal of Clinical Oncology 2010, 28:1254-1261.
77. Gaafar R., Bahnassy A., Abdelsalam I., et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer 2010, 70:43-50.
78. Okuda K., Sasaki H., Kawano O., et al. Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma. J Cancer Res Clin Oncol 2008, 134:1105-1111.
79. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 2006, 51:207-215.
80. O'Byrne K.J., Edwards J.G., Waller D.A. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004, 45(Suppl. 1):S45-S48.
81. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 1990, 61:924-926.
82. Edwards J.G., Swinson D.E., Jones J.L., Waller D.A., O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407.
83. Janne P.A., Taffaro M.L., Salgia R., Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 2002, 62:5242-5247.
84. Cole G.W., Alleva A.M., Reddy R.M., et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 2005, 129:1010-1017.
85. Govindan R., Kratzke R.A., Herndon J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005, 11:2300-2304.
86. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., Suzuki Y., Vogelzang N.J. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
87. Garland L.L., Rankin C., Gandara D.R., et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007, 25:2406-2413.
88. Cortese J.F., Gowda A.L., Wali A., Eliason J.F., Pass H.I., Everson R.B. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 2006, 118:521-522.
89. Metcalf R.A., Welsh J.A., Bennett W.P., et al. P53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992, 52:2610-2615.
90. Kitamura F., Araki S., Tanigawa T., Miura H., Akabane H., Iwasaki R. Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos-PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors. Ind Health 1998, 36:52-56.
91. Kitamura F., Araki S., Suzuki Y., Yokoyama K., Tanigawa T., Iwasaki R. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 2002, 40:175-181.
92. Ni Z., Liu Y., Keshava N., Zhou G., Whong W., Ong T. Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 2000, 468:87-92.
93. Dote H., Tsukuda K., Toyooka S., Yano M., Pass H.I., Shimizu N. Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP. Oncol Rep 2004, 11:361-363.
94. Yutaro Suzuki, Hideki Murakami, Koji Kawaguchi, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009, 2:181-188.
95. Altomare D.A., You H., Xiao G.H., et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005, 24:6080-6089.
96. Opitz I., Soltermann A., Abaecherli M., et al. PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506.
97. Kono S.A., Marshall M.E., Ware K.E., Heasley L.E. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat 2009, 12:95-102.
98. Eyzaguirre A., Buck E., Iwata K., Haley J., Miglarese M. Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. Target Oncol 2008, 3:235-243.
99. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14:2895-2899.
100. Jagadeeswaran R., Ma P.C., Seiwert T.Y., et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006, 66:352-361.
101. Hoang C.D., Zhang X., Scott P.D., et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004, 64:7479-7485.
102. Whitson B.A., Jacobson B.A., Frizelle S., et al. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic surgery directors association resident research award. Ann Thorac Surg 2006, 82:996-1001. [discussion-2].
103. Kai K., D'Costa S., Sills R.C., Kim Y. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett 2009, 278:49-55.
104. Dannenberg A.J., Lippman S.M., Mann J.R., Subbaramaiah K., DuBois R.N. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23:254-266.
105. Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur J Cancer 2005, 41:1854-1863.
106. Amir M., Agarwal H.K. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 2005, 60:563-570.
107. Gasparini G., Longo R., Sarmiento R., Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol 2003, 4:605-615.
108. Baldi A., Santini D., Vasaturo F., et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004, 59:428-433.
109. Edwards J.G., Faux S.P., Plummer S.M., et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002, 8:1857-1862.
110. O'Kane S.L., Cawkwell L., Campbell A., Lind M.J. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005, 41:1645-1648.
111. Catalano A., Graciotti L., Rinaldi L., et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004, 109:322-328.
112. O'Kane S.L., Eagle G.L., Greenman J., Lind M.J., Cawkwell L. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010, 67:160-165.
113. Wirth L.J., Haddad R.I., Lindeman N.I., et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005, 23:6976-6981.
114. Gadgeel S.M., Ruckdeschel J.C., Heath E.I., Heilbrun L.K., Venkatramanamoorthy R., Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:299-305.
115. O'Byrne K.J., Danson S., Dunlop D., et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol 2007, 25:3266-3273.
116. Reckamp K.L., Krysan K., Morrow J.D., et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 2006, 12:3381-3388.